Navigation Links
Mayo Clinic CEO Offers New Vision for Personalized Patient Care
Date:3/4/2009

WASHINGTON, March 4 /PRNewswire/ -- Denis A. Cortese, M.D., president and CEO of the Mayo Clinic, offered a new vision for personalized healthcare in America at a time when Congress and the administration are discussing changes in the healthcare system.

The Mayo Clinic is committed to implementing personalized medicine for its patients. By targeting specific treatments to individual patients based on an analysis of differences in their molecular makeup, personalized medicine increases the effectiveness and safety of many existing therapies and spurs the creation of new treatments.

Dr. Cortese was introduced by Paul Stoffels, M.D., company group chairman, global pharmaceutical research and development, Johnson & Johnson. Dr. Stoffels said that Johnson & Johnson is committed to a personalized approach to medicine, using its broad expertise in healthcare research and development to develop targeted therapies for major diseases.

The keynote address at the Personalized Medicine Coalition's annual luncheon took place against the backdrop of the Obama Administration's health reform summit, which the president announced last week in his address to Congress. Johnson & Johnson sponsored the luncheon, which was held at the National Press Club.

Dr. Cortese discussed how Mayo Clinic's implementation of personalized medicine works in practice and what it means for Mayo's patients. He emphasized the importance of interoperable computerized patient records and communication among different providers in determining the optimal treatments for individual patients.

"Health information technology plays a huge role in synthesizing large amounts of data, creating knowledge that will drive evidence-based decision making," Dr. Cortese said.

These insights should guide spending for two sums in the economic stimulus package: $19.2 billion for health information tech
'/>"/>

SOURCE Personalized Medicine Coalition
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
2. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
3. Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform
4. Clinical Research Staffing Firm ASG Acquires CRO Ockham Development Group
5. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
6. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
7. Implicit Licenses Clinical Stage Antibody Program From Lilly
8. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
9. Charlotte Anti-Aging Expo & Symposium Supports Free Clinics
10. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
11. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2
... weather information businesses have launched an integrated traffic and weather ... RouteCast , the platform of Weather Central, Inc. ... viewers to a station's on-air, online, mobile, desktop, and digital ... the platform was used to customize a solution for ...
... - The Medical College of Wisconsin has ... study pain relief methods for patients with advanced cancer. , ... care consultation teams, the study will seek to find the ... patient and family goal-setting, and satisfaction with care. , ,The ...
... Sharon, Wis. - Global Renewable LLC, a Whitewater, Wis. ... unveiled plans to build and operate a $195 million ethanol ... , ,Pending municipal approvals, the Sharon Ethanol Plant annually would ... would create an estimated 55 new full-time jobs and more ...
Cached Biology Technology:
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... issue of Genes & Development, Dr. Mary Ellen Perry ... promising target for cancer therapies. , The p53 tumor ... many anticancer strategies aim to activate p53 in order ... of p53 and therefore an attractive target to modulate ...
... physicists at the University of California, San Diego has shown ... as it passes through tiny pores. The advance brings ... in the April issue of the journal Nano Letters, describes ... of hours at a potentially low cost, by measuring the ...
... serious suicide attempts or death by suicide generally decreases ... according to a new study led by Group Health ... The American Journal of Psychiatry. The study also found ... newer antidepressant medications is less than the risk posed ...
Cached Biology News:Nanopore method could revolutionize genome sequencing 2Nanopore method could revolutionize genome sequencing 3Suicide risk does not increase when adults start using antidepressants, study finds 2
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Rabbit polyclonal to ErbB 2 - ... for all tested applications). ... AENPEYLGLDVPV conjugated to KLH, corresponding to ... Human c-ErbB2 Entrez ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Biology Products: